Rapid Discovery of Functional Antibodies for SARS-CoV-2 Using the Beacon System

In this GEN webinar, sponsored by Berkeley Lights, we will hear from Anupam Singhal, PhD, who will provide a brief overview of how antibody discovery on the Beacon optofluidic system can be used to screen human B cells for the discovery of antiviral antibodies in under one week. Robert Carnahan, PhD, and Seth Zost, PhD, from the Vanderbilt University Medical Center, will then describe how they have used the Beacon system, to rapidly discover hundreds of unique antibodies against SARS-CoV-2.

The Successful Evolution of Biotherapies from Discovery to Development

In this GEN webinar, sponsored by Lonza, we will examine initial strategies to optimize the amino acid sequence of biotherapeutic molecules, along with techniques to maximize product quality through expression vector design. One tool, GS piggyBac™, which can help improve expression levels, especially for more complex, next-generation biologics, will be discussed.

Streamlining High-Throughput Impurity Analysis in Process Development

In this GEN webinar, we will hear about some of the latest advances in high-throughput analytics, with particular attention on the High-Throughput Impurity Detection platform for automated impurity quantitation from Lonza.

Measuring Multivalent Interactions: Uncovering the Secrets of Virus Binding Strategies

In this GEN webinar, we will learn from Dr. Daniel Lauster, who, when faced with many of the challenges described above, utilized MicroScale Thermophoresis (MST) to measure the interaction between more than 100 novel non-toxic multivalent nanoparticle-conjugates and intact IAV in solution with as little as nanomoles of nanoparticles. Additionally, we will hear from Dr. Matthias Molnar how MST is becoming scientists’ first choice for the characterization of molecular interactions thanks to its flexible throughput, low sample consumption, and measurements in solution or in close to native conditions.

Recent Advances and the Future of Antibody Engineering

In this GEN webinar, we will hear from Danica Stanimirovic MD, PhD, and Danica Stanimirovic MD, PhD, wto leading scientists who will describe their current antibody engineering research projects and the therapeutic potential they hold.

Association Rate Constant: The Unsung Hero of Drug Discovery Kinetics

While the importance of ligand-receptor binding kinetics on drug action is becoming well established, focus to date has been almost entirely on the role of the dissociation constant on drug efficacy and duration of action. The association rate constant, in contrast, has been largely overlooked, with many investigators still considering it diffusion-limited and equivalent across a compound series. This GEN webinar aims to remedy that by turning the spotlight onto the undervalued and oft-ignored association rate constant.

Grünenthal Acquires Partial Rights to Nexium, Vimovo from AstraZeneca for Up-to-$922M

Grünenthal has agreed to acquire AstraZeneca’s European rights to Nexium®(esomeprazole) and the pharma giant’s rights to Vimovo® (naproxen/esomeprazole) worldwide except the U.S. and Japan...

Parkinson’s Disease Drug That Cools “Brains on Fire” Could Enter Human...

Researchers at the University of Queensland in Australia have identified a small molecule that can stop the progression of Parkinson’s disease (PD) and improve...

Zika’s Balloon Popped by Peptide Needle

A new antiviral drug candidate attacks the Zika virus where it may be most vulnerable—the lipid membrane, which envelopes Zika’s RNA payload. The drug...

Conjoined Cells Form a Potent Immunotherapy Combo

Shackled together, stem cells and platelets may help us escape cancer, report UCLA scientists. In the scientists’ new study, the cancer is leukemia, and...
Scroll Up